554 related articles for article (PubMed ID: 17981670)
21. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.
Bordet R; Ouk T; Petrault O; Gelé P; Gautier S; Laprais M; Deplanque D; Duriez P; Staels B; Fruchart JC; Bastide M
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1341-6. PubMed ID: 17073815
[TBL] [Abstract][Full Text] [Related]
22. Hormone regulation of microglial cell activation: relevance to multiple sclerosis.
Drew PD; Storer PD; Xu J; Chavis JA
Brain Res Brain Res Rev; 2005 Apr; 48(2):322-7. PubMed ID: 15850670
[TBL] [Abstract][Full Text] [Related]
23. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.
Takano H; Hasegawa H; Zou Y; Komuro I
Curr Pharm Des; 2004; 10(22):2779-86. PubMed ID: 15320743
[TBL] [Abstract][Full Text] [Related]
24. [The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis].
Knapp P; Jarzabek K; Błachnio A; Zbroch T
Ginekol Pol; 2006 Aug; 77(8):643-51. PubMed ID: 17076197
[TBL] [Abstract][Full Text] [Related]
25. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma).
Patel KM; Wright KL; Whittaker P; Chakravarty P; Watson ML; Ward SG
Cell Signal; 2005 Sep; 17(9):1098-110. PubMed ID: 15993751
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells.
Guo B; Koya D; Isono M; Sugimoto T; Kashiwagi A; Haneda M
Diabetes; 2004 Jan; 53(1):200-8. PubMed ID: 14693716
[TBL] [Abstract][Full Text] [Related]
27. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
Li Y; Wen X; Spataro BC; Hu K; Dai C; Liu Y
J Am Soc Nephrol; 2006 Jan; 17(1):54-65. PubMed ID: 16291834
[TBL] [Abstract][Full Text] [Related]
28. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
29. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362
[TBL] [Abstract][Full Text] [Related]
30. The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Shehata AHF; Ahmed AF; Abdelrehim AB; Heeba GH
Life Sci; 2020 Jul; 252():117679. PubMed ID: 32325134
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury.
Genovese T; Esposito E; Mazzon E; Di Paola R; Muià C; Meli R; Bramanti P; Cuzzocrea S
Shock; 2008 Aug; 30(2):142-52. PubMed ID: 18628687
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
34. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats.
Liu H; Rose ME; Culver S; Ma X; Dixon CE; Graham SH
Biochem Biophys Res Commun; 2016 Apr; 472(4):648-55. PubMed ID: 26947332
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects.
Calabrò P; Samudio I; Safe SH; Willerson JT; Yeh ET
J Vasc Res; 2005; 42(6):509-16. PubMed ID: 16155367
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis.
Storer PD; Xu J; Chavis J; Drew PD
J Neuroimmunol; 2005 Apr; 161(1-2):113-22. PubMed ID: 15748950
[TBL] [Abstract][Full Text] [Related]
38. Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.
Basilotta R; Lanza M; Casili G; Chisari G; Munao S; Colarossi L; Cucinotta L; Campolo M; Esposito E; Paterniti I
Cells; 2022 Feb; 11(4):. PubMed ID: 35203272
[TBL] [Abstract][Full Text] [Related]
39. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms.
Pereira MP; Hurtado O; Cárdenas A; Boscá L; Castillo J; Dávalos A; Vivancos J; Serena J; Lorenzo P; Lizasoain I; Moro MA
J Cereb Blood Flow Metab; 2006 Feb; 26(2):218-29. PubMed ID: 16034372
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists.
Chana RS; Lewington AJ; Brunskill NJ
Kidney Int; 2004 Jun; 65(6):2081-90. PubMed ID: 15149321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
